Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18957357 | 0.94 | TSHR (0.34) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18957356 | 0.94 | TSHR (0.34) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18957028 | 0.93 | TSHR (0.34) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18957029 | 0.93 | TSHR (0.34) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18966539 | 0.92 | TSHR (0.31) | TSHRTDP1L3MBTL1 | |
| SCHEMBL18957221 | 0.91 | TRPA1 (0.33) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18957222 | 0.91 | TRPA1 (0.33) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL23129965 | 0.91 | TSHR (0.37) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL17347706 | 0.91 | TSHR (0.37) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 | |
| SCHEMBL18957413 | 0.90 | TSHR (0.33) | TSHRTDP1L3MBTL1TRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464952-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | TSHR 4759/4885TDP1 1647/4885L3MBTL1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.